A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL.
The file type is
Mesenchymal stromal cells have become a candidate for cell therapy due to potent immunomodulatory properties exhibited in their secretome. However, they have shown limited clinical success due to issues of dosing and persistence when administered in vivo. A scalable hollow fiber bioreactor device has been created to deliver MSC therapeutics in an ex vivo manner. The potency and behavior of MSCs in this bioreactor can be explored via a dynamic perfusion system, collecting the MSC secretome indoi:10.7282/t3-66d1-ra75 fatcat:nxpqedknyfalfag4glpfjerfku